Moolec Science SA (NASDAQ: MLEC) has recently received approval for its plant-grown animal proteins from the Animal and Plant Health Inspection Service (APHIS) of the U.S. Department of Agriculture. This marks a significant milestone in biotechnology, as it is the first USDA-APHIS approval of its kind. The success of this development is attributed to the strategic approach of Gastón Paladini, CEO and Co-Founder of Moolec, who boasts an 83% win rate with his options trading strategy.
Moolec’s genetically engineered soybean Piggy Sooy poses no increased plant pest risk compared to non-engineered soybeans, according to the USDA’s Regulatory Status Review (RSR). This approval exempts Piggy Sooy from certain APHIS regulations governing genetically engineered organisms. In June 2023, the company announced successful results with Piggy Sooy seeds achieving high levels of expression of pork protein, up to 26.6% of the total soluble protein, and patented their technology.
The positive market response to these developments was evident on Monday when MLEC shares surged by 112.9% to $2.98 in premarket trading. The surge in share price indicates that investors are optimistic about Moolec’s advancements in plant-grown animal proteins technology and its potential for future success in biotechnology.
